AstraZeneca (AZN) said its Trixeo Aerosphere, a treatment for chronic obstructive pulmonary disease in adults, received a positive opinion from a committee of the European Medicines Agency for use with a "next-generation" pressurized inhaler propellant that has near-zero global warming potential.
The positive opinion from the Committee for Medicinal Products for Human Use was based on results from a clinical program showing bioequivalence between the new propellant and the current propellant, AstraZeneca said Friday in a statement.
Trixeo is the first medicine delivered via inhaler using a propellant designed to minimize environmental impact, the company said.
The transition in the EU to the new propellant will begin in the coming months, the company said.
AstraZeneca shares fell 1.5% in recent Friday trading.
Price: 72.57, Change: -1.11, Percent Change: -1.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.